Research at risk


This report from UK think tank IPPR looks at how to mitigate the impact of Covid-19 on health R&D investment.

There is every reason to increase the role of R&D in the UK economy. Even before we think about high-impact events like Covid-19 and Brexit, the country faced a significant productivity challenge. Normally, after a fiscal crisis, productivity recovers. However, after the 2008 crisis, we observed ‘productivity hysteresis’ – whereby the negative impact on productivity became permanent. This is a problem for living standards, wage growth, public sector sustainability and our ability to compete in the global economy. Yet, R&D – and particularly health research – is also an excellent antidote to the challenges facing the UK. Covid-19 has created a substantial health backlog, which may impact outcomes for years or decades to come. New discoveries and a renewed focus on improving health outcomes is one way to begin rectifying this. Moreover, Covid-19 has proven the importance of health resilience – to the economy, to our health and to our way of living. A stronger health sector, with more thinkers, more lab space, more capacity and more agility is a good way to support that.

Read Full Report

Explore our reports

  • Reset
Advanced search

Related Events

Wed

20

Oct

Acting now for green, inclusive growth

This event, hosted by UK think tank the CPP will examine new and evolving challenges and identify innovative solutions for…

More Info